Journals / Nöropsikiyatri Arşivi / 2016 / Cilt: 53 - Sayı: 4

Bipolar Bozukluk Tanılı 11 Yaşındaki Çocukta Uzun Etkili Enjektabl Risperidon Kullanımı

Long-acting Injectable Risperidone Use in an 11-Years-Old Bipolar Child

Pages
361–363
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Long-acting injectable risperidone use in the case of nonadherence to treatment and observed side effects will be discussed

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Early-onset bipolar disorder is difficult for child psychiatrists in terms of both diagnosis and treatment.
📊
Key Findings & Data:Risperidone is a commonly used atypical antipsychotic it has been approved for the treatment of manic and mixed episodes of bipolar disorder even in 10–17-year-old patients, and it is commonly used.
💡
Conclusion & Impact:Long-acting injectable risperidone use in the case of nonadherence to treatment and observed side effects will be discussed
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Early-onset bipolar disorder is difficult for child psychiatrists in terms of both diagnosis and treatment. The proper diagnostic evaluation is negatively impacted by the atypical clinical manifestation and rapid cycling pattern of the disease, together with common comorbidity with attention-deficit hyperactivity disorder and anxiety disorder. In addition to poor insight, nonadherence to treatment, poor family coping skills, and insufficient child psychiatric inpatient units make clinicians unsuccessful in following up and treating such patients. Risperidone is a commonly used atypical antipsychotic it has been approved for the treatment of manic and mixed episodes of bipolar disorder even in 10–17-year-old patients, and it is commonly used. It has a long-acting injectable formulation. Studies on its long-acting form in younger children are limited. In this case presentation, the diagnostic procedure in an 11-year old child with bipolar disorder will be presented. Long-acting injectable risperidone use in the case of nonadherence to treatment and observed side effects will be discussed

Özet

Erken başlangıçlı bipolar bozukluk gerek tanı, gerekse tedavi anlamında çocuk psikiyatrisi uzmanları için zorlayıcı olabilmektedir. Hastalığın atipik klinik görünümü, hızlı döngülü olması, dikkat eksikliği hiperaktivite bozukluğu ve anksiyete bozuklukları ile yüksek komorbiditeye sahip olması tanı konma sürecini olumsuz etkilemektedir. Çocuklarda içgörü yokluğu, tedaviye uyumsuzluk, ailenin baş etme becerilerinin zayıf olmasının yanı sıra, çocuk hastalar için yataklı servis eksiklikleri nedeniyle erken başlangıçlı bipolar bozukluğun ayaktan tedavisi ve takibi zordur. Risperidon, sık kullanılan atipik antipsikotiklerden olup 10-17 yaş arası bipolar bozukluk manik ve karma dönemlerinin tedavisinde onay almıştır. İlacın uzun etkili enjektabl formu mevcuttur. Uzun etkili formunun erken yaşlarda kullanımı ile çalışmalar nadirdir. Bu olgu sunumunda 11 yaşındaki bir çocuğun bipolar bozukluk tanı süreci ve tedavisi anlatılacaktır. Tedaviye uyumsuzluğu sonucunda kullanılan uzun etkili risperidon enjeksiyonunun etkinliği ve karşılaşılmış olan yan etkileri tartışılacaktır.

🔖

Cite This Article

DEMİRKAYA, S. K., ZOROĞLU, S. S. (2016). Bipolar Bozukluk Tanılı 11 Yaşındaki Çocukta Uzun Etkili Enjektabl Risperidon Kullanımı. Nöropsikiyatri Arşivi, Cilt: 53 - Sayı: 4, 361–363. https://ajindex.com/articles/292439

References (13)

  1. Perlis RH, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, DelBello MP, Bowden CL, Sachs GS, Nierenberg AA
  2. STEP-BD Investigators. Longterm implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2004
  3. [CrossRef] 2. Bishop JR, Pavuluri MN. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatr Dis Treat 2008
  4. Findling RL, McNamara NK. Atypical Antipsychotics in the Treatment of Children and Adolescents: clinical applications. J Clin Psychiatry 2004
  5. 65(Suppl 6):30-44. 4. Biederman J, Mick E, Wosniak J, Aleardi M, Spencer T, Faraone SV. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005
  6. [CrossRef] 5. Fu IL, Boarati MA, Stravogiannis A, Wang YP. Use of Risperidone LongActing Injection to support Treatment Adherence and Mood Stabilization in Pediatric Bipolar Patients: a Case Series. J Clin Psychiatry 2009
  7. [CrossRef] 6. Kaufman J, Birmaher B, Brent D, Rau U, Ryan N. Schedule for affective disorders and schizophrenia for school age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997
  8. [CrossRef] 7. Gokler B, Unal F, Pehlivanturk B, Çengel Kültür E, Akdemir D, Taner Y. Reliability and validity of Schedule for Affective Disorders and Schizophrenia for School Age Children-Present and Lifetime Version - Turkish Version (K-SADS-PL-T). Turk J Child Adolesc Ment Health 2004
  9. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978
  10. [CrossRef] 9. Karadag F, Oral ET, Aran Yalcın F, Erten E. Reliability and validity of young mania rating scale- Turkish version. Turk J Psychiatry 2001
  11. Geller B, Zimerman B, Williams B, Frazier J, Beringer L, Warner KL. Prepubertal and early adolescent bipolarity differentiate from ADHD by manic symptoms, grandiose delusions, ultrarapid or ultradian cycling. J Affect Disord 1998
  12. [CrossRef] 11. Kemp DE, Canan F, Goldstein B, McIntyre RS. Long-acting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther 2009
  13. [CrossRef] 12. Correll CU. Weight gain and metabolic effects of mo